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We have  investigated  the mechanism by which vita- 
min Be acts to modulate steroid hormone-mediated 
gene expression. We show that  the level of glucocorti- 
coid-induced gene expression  from simple promoters, 
containing only hormone response elements and a 
TATA sequence, was not affected by alterations in 
intracellular  vitamin Be concentration. However, mod- 
ulation of hormone-induced gene expression  was re- 
stored  with  the inclusion of a binding site for  the  tran- 
scription  factor  nuclear  factor 1 (NF1) within the hor- 
mone-responsive promoter; glucocorticoid-induced 
gene expression was reduced by 44% under conditions 
of elevated  intracellular  vitamin Be concentration and 
enhanced by 98% in mild vitamin deficiency. Under 
these conditions, neither glucocorticoid receptor sedi- 
mentation  characteristics,  receptor  activation,  nor 
DNA binding capacity was affected. Quantitatively 
analogous effects  were detected with estrogen-induced 
gene expression when an NF1 binding site was re- 
moved from or introduced  into an estrogen-responsive 
promoter. NF1-mediated constitutive  transcription 
was not affected by alterations  in  vitamin  concentra- 
tion. The modulatory effect of vitamin  did not require 
strict positioning of or spacing between the glucocor- 
ticoid response element and  NF1  binding  site. More- 
over, a heterologous transcriptional activator, com- 
posed of the  viral E l a  transactivation domain and  the 
GAL4 DNA binding domain, does not substitute  for 
NF1  in  restoring  vitamin Be modulation of hormone- 
induced gene expression. These results suggest that 
vitamin Be modulates steroid hormone-mediated gene 
expression through its influence on a functional or 
cooperative interaction between steroid hormone 
receptors  and  the  transcription  factor NF1. 
Steroid hormones regulate a variety of physiological proc- 
esses that  are involved in growth, development, and  mainte- 
nance of homeostasis (1). The biological effects of steroid 
hormones are achieved through  interaction with their  intra- 
cellular receptor molecules. Although unique receptor proteins 
exist for each steroid hormone, the steroid hormone receptors, 
nonetheless all exhibit remarkable similarities in structure, 
function,  and sequence (2-6). Binding of the steroid ligand 
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initiates the process of transformation, through which the 
steroid hormone receptor acquires affinity for specific DNA 
sequences, termed hormone response elements. Interaction of 
the receptors with their corresponding hormone response 
elements  results in the modulation of specific gene expression, 
through which the physiological effects of steroid hormones 
are mediated. 
Early  studies  demonstrated that interaction of the steroid 
hormone receptor with the hormone response element renders 
a linked heterologous gene hormonally responsive (7, 8). Al- 
though the precise mechanism underlying this response has 
not been defined, it is clear that  the hormone effect is manifest 
as increased transcription (9, 10). Subsequent investigations 
demonstrate that interaction of the receptor with its response 
element is only part of the physiological process of steroid 
hormone action. The promoters of known hormonally regu- 
lated genes are complex, with binding sites for transcription 
factors in addition to  the steroid hormone receptor, indicating 
that other transcriptional regulatory elements are also in- 
volved in mediating the response to hormone (11-15). For 
example, the glucocorticoid-inducible mouse mammary tumor 
virus  (MMTV)’ long terminal  repeat  and the estrogen-induc- 
ible vitellogenin gene promoter both  contain  a binding site 
for the transcription factor nuclear factor 1 (NF1) (16, 17), 
and  mutations of this  site influence the ability of these pro- 
moters to respond to hormone. Similarly, the promoters for 
two other glucocorticoid-inducible genes, tyrosine amino- 
transferase  and  tryptophan oxygenase, each contains  a bind- 
ing  site,  a CACCC element, for another  transcription factor 
adjacent to  the glucocorticoid response element (GRE) (18- 
20). Removal of this sequence also interferes with glucocor- 
ticoid induction of transcription of these genes. The steroid- 
inducible ovalbumin gene promoter contains binding sites for 
both the COUP  transcription factor (21) and  NF1 (22), both 
of which are  important for both in uiuo and in vitro transcrip- 
tion of the gene. Cooperative interactions between steroid 
hormone receptors and  other  transcription factors may thus 
provide another  step at which steroid receptor function may 
be regulated. 
We have shown recently that transcriptional activation by 
steroid hormone receptors is inversely modulated by altera- 
tions  in the intracellular  concentration of pyridoxal 5“phos- 
phate, the physiologically active form of vitamin Be (23, 24). 
We found reduced levels of hormone-mediated gene expres- 
sion under conditions of elevated vitamin concentration  and 
enhanced hormone responsiveness under conditions of vita- 
min deficiency.  We have now sought to determine the mech- 
anism through which the vitamin Bs concentration affects 
’The abbreviations used are: MMTV, mouse mammary tumor 
virus; NF1, nuclear factor 1; GRE, glucocorticoid response element; 
CAT, chloramphenicol acetyltransferase; TF, transcription factor. 
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transcriptional activation by steroid hormone receptors by 
examining the effect of intracellular vitamin concentration 
on receptor-induced gene expression mediated through  both 
complex and simple promoters. Results from these studies 
demonstrate that  the modulation of receptor-induced gene 
expression by vitamin B6 requires promoter  elements  in  ad- 
dition to  the hormone response element. Cooperation or func- 
tional  interaction between the hormone receptor and at least 
one other  transcription factor, NF1, is essential for pyridoxal 
phosphate to influence transcriptional  activation by steroid 
hormone receptors. 
EXPERIMENTAL  PROCEDURES 
Materials-Acetyl-coenzyme A was from Pharmacia  LKB Biotech- 
nology Inc. Pyridoxine and 4-deoxypyridoxine were from Sigma. 
Dexamethasone and 170-estradiol were from Steraloids. DNA-modi- 
fying enzymes were from Life Technologies, Inc. [‘4C]Chloramphen- 
icol (40-60 mCi/mmol) was obtained from Du Pont-New England 
Nuclear. =S-dATP (600 Ci/mmol) was from Amersham Corp. [3H] 
Dexamethasone (46/Ci/mmol) was from Du Pont-New  England Nu- 
clear. Sequenase was from U. s. Biochemical Corp. Other reagents 
were from Fisher Scientific or Sigma. 
Recombinant Plasmids-The plasmid pElbCAT (25), the generous 
gift of Dr. James Lillie, served as  the vector for all of the recombinant 
plasmids generated for this work. This vector contains the adenovirus 
Elb  TATA sequence (5’-AGGGTATATAATG-3’) inserted immedi- 
ately  upstream of the chloramphenicol acetyltransferase  (CAT) gene 
in pSP72 (Promega). The plasmids pGRE2CAT and pGRE3CAT 
were created by inserting two or three copies, respectively, of an 
oligonucleotide encompassing the GRE sequence from the tyrosine 
aminotransferase gene 5’-TGTACAGGATGTTCT-3’ (26) into the 
Hind111 site of pElbCAT. pGRE2NFlCAT was generated by intro- 
ducing an oligonucleotide containing the  NF1 binding site derived 
from the MMTV promoter, 5”CTTCTTTTGGAATTTATCCAAA 
TCTTATGTT-3’ (27), between the proximal GRE and  the TATA 
box in pGRE2CAT. pNFlGRE2CAT was created by cloning the same 
oligonucleotide containing the  NF1 binding site immediately 5’  to 
the distal GRE. pNFlCAT was created by inserting the  NF1 oligo- 
nucleotide into  the  parent vector pElbCAT.  The estrogen-inducible 
vector pERECAT was created by cloning the vitellogenin AP promoter 
fragment (-331 to -87) into  pE1bCAT  pERENFlCAT was gener- 
ated by introducing the  NF1 oligonucleotide between the vitellogenin 
fragment and  the TATA box in pERECAT. pGRE2GAL4CAT was 
created by cloning an oligonucleotide comprising a binding site for 
GAL4, 5’-CGGAGTACTGTCCTCCGCTCGAC-3’ (25), between 
the proximal GRE and  the TATA box in pGRE2CAT. Sequences of 
all constructed plasmids were verified by sequence analysis. pGMCS 
(28, 29), obtained from Dr. Keith Yamamoto, contains the MMTV 
long terminal repeat directing expression of the CAT gene. pBLCAT2 
(30), from Drs. Bruno Luckow and Gunther Schutz, contains the 
thymidine kinase promoter driving expression of the CAT gene. 
pHEO, the human estrogen receptor expression vector, was obtained 
from Dr. Pierre Chambon (31). The plasmid pGAL4Ela (25), which 
directs production of the chimaeric GAL4Ela  transcriptional  acti- 
vator, was also provided by Dr. James Lillie. 
Cell Culture-HeLa Ss cells were  grown as monolayer cultures as 
described previously (23). Pyridoxine and 4-deoxypyridoxine were 
dissolved in water and diluted into  the culture media where indicated 
to final concentrations of 1 and 5 mM, respectively. Dexamethasone 
was dissolved in water and  its concentration  determined spectopho- 
tometrically; it was added to  the culture medium where indicated to 
a  final  concentration of 100 nM for 8 h. 17P-Estradiol was dissolved 
in  ethanol and added to culture medium where indicated to a  final 
concentration of 5 nM for 24 h. 
Cell Transfections-HeLa cells were transfected by calcium phos- 
phate precipitation as described previously (23) using 5 pg of CAT 
reporter plasrnid/lOO-mm culture dish. For studies with the estrogen 
receptor, cells were cotransfected with 5 pg of estrogen-responsive 
CAT reporter and 10 pg  of pHEO/lOO-mm dish. For studies with the 
chimaeric transactivator  protein, cells were cotransfected with 5 pg 
of pGRE2GAL4CAT and 5 pg  of pGAL4Ela/lOO-mm dish. Sixteen 
hours after transfection, the cell culture media were supplemented 
with either pyridoxine (1 mM), 4-deoxypyridoxine (5 mM), or vehicle 
(HzO). After incubation for 38 h, cells were exposed to hormone as 
indicated in the text and figure legends prior to determination of 
CAT activity. 
transfected with either pGMCS, pGREZCAT,  pGREBCAT, 
Determination of CAT Actiuity-CAT activity from HeLa cells 
pGREBNFlCAT, pNFlGREBCAT, pERECAT, or pERENFlCAT 
was determined as described previously (23,  24) using 500  pg  of cell 
extract/reaction. 100 pg and 50 pg of cell extract were used in the 
assays from cells transfected with the GAL4-containing or pBLCAT2 
constructs, respectively. CAT activity was quantitated by excising the 
appropriate  area from the  thin layer chromatography plate and quan- 
titating “C  by scintillation counting; the portion of total [”C]chlor- 
amphenicol converted to  an acetylated form is representative of the 
level of induced CAT activity. 
Cytosol and Sucrose Density Gradient Preparation-HeLa Sa cells 
were grown as described (23). Eighteen hours prior to harvesting, 
pyridoxine was added to  the medium of designated cells that were 
approximately 75-80% confluent. The cells were then harvested and 
incubated with 100 nM [3H]dexamethasone, and activated and  non- 
activated cytoplasmic glucocorticoid receptors were prepared (32). 
The activated receptors were then incubated without or with a 1,200- 
base pair fragment of DNA, obtained from an Ssp1 digest of 
pGREBNFlCAT, containing the two GREs and  the NF1  site. Aliquots 
of cytosol (0.27 ml) were layered onto 10-25% sucrose density gra- 
dients, centrifuged, fractionated, and quantitated as described (33). 
RESULTS 
Glucocorticoid-induced expression of reporter genes linked 
to  the MMTV promoter is mediated at  the level of initiation 
of gene transcription  and is dependent on the interaction of 
the receptor with GREs  contained in the MMTV promoter 
(7,9, 10). To determine if alterations in glucocorticoid  recep- 
tor binding to GRE  sites  in DNA represented the mechanism 
through which the vitamin Bs acted to influence glucocorti- 
coid-induced gene expression, we constructed CAT reporter 
plasmids whose promoters were significantly less complex 
than  the MMTV promoter used previously (23, 24). These 
plasmids, pGRE2CAT and pGRE3CAT, have promoters com- 
prised of two and three copies, respectively, of the GRE 
consensus sequence derived from the glucocorticoid-inducible 
tyrosine aminotransferase gene (26). A binding site for the 
ubiquitous transcription factor TFIID is located immediately 
upstream of the CAT gene to direct accurate transcription 
initiation. When transfected into HeLa cells, both of the 
“minimal promoter”-driven vectors supported glucocorticoid- 
induced, receptor-mediated CAT gene expression. Table I 
shows that  the magnitude of induction with these two vectors 
was quantitatively similar to  that obtained with CAT gene 
expression and was induced through the complex MMTV 
promoter in pGMCS. The parent vector pElbCAT, which 
does not  contain receptor binding sites, was not responsive to 
glucocorticoid treatment.  The similarity in hormone respon- 
siveness through the  three different promoters demonstrated 
that  the glucocorticoid receptor was  fully capable of binding 
to  the GREs contained in the two minimal promoters and 
inducing transcription of the heterologous target gene despite 
TABLE I 
Glucocorticoid-regulated gene expression from complex and simple 
promoters 
HeLa cells were transfected with each of the plasmids as indicated. 
Forty-eight hours after transfection, the cells were exposed to 100 nM 
dexamethasone or vehicle for 8 h prior to determination of CAT 
activity. The data shown represent the average from at least four 
independent  determinations from a minimum of two exueriments. 
Plasmid Control Dexamethasone Induction 
~~ 
-fold 
pGMCS 0.8 f 0.27  15.6 * 1.3 
pGRE2CAT 1.14 f 0.32 
19.5 
23.9 f 7.8  20.9 
pGRE3CAT 0.63 f 0.2  11.9 f 3.5  18.9 
pElbCAT <o. 1 <0.1 
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the absence of binding sites for other ancillary transcription 
factors. 
We then asked if the receptor-dependent  transcription  in- 
duced by each of the constructs was susceptible to modulation 
by vitamin B6. After transfection of these three reporter 
vectors into HeLa cells, the intracellular pyridoxal phosphate 
concentration was either increased or reduced as described 
previously (23). The  data  in Fig. 1 show that  treatment with 
dexamethasone in control medium results  in an approximate 
12-fold induction in CAT activity. Under vitamin conditions 
that approximately double the intracellular pyridoxal phos- 
phate  concentration, the level of glucocorticoid receptor-in- 
duced CAT gene expression through the complex MMTV 
promoter (pGMCS) was only 5-fold, a reduction to 41% of 
that observed with dexamethasone treatment in unaltered 
medium. Conversely, mild vitamin deficiency resulted in an 
approximate 46% enhancement, represented by the 27-fold 
induction, in  the level of receptor-induced gene expression. 
In contrast, the level of receptor-induced gene expression 
derived from the vectors containing the simplified promoters, 
pGRE2CAT or pGRESCAT, was not affected by these same 
alterations in vitamin concentration. These studies suggest 
that two functions of the glucocorticoid receptor, its capacity 
to interact with DNA i n  uiuo, and its ability to activate 
transcription, were not affected by alterations  in  vitamin B6 
concentration. Interestingly,  neither  basal (glucocorticoid-in- 
dependent) CAT expression nor constitutive expression, from 
pBLCAT2, is affected by vitamin  concentration, eliminating 
possible effects of the vitamin on transcription factors in- 
volved in basal or constitutive gene expression. 
These differences in  vitamin effects on transcription me- 
diated  through the complex uersus the simple promoters sug- 
gested that some additional  step(s) must be  involved in  in- 
duction of gene expression from the complex promoter. Cor- 
dingley et al. (27) have demonstrated that  in addition to  the 
GREs, two other regions of the MMTV promoter are pro- 
tected in whole cells as  a  result of exposure to glucocorticoid. 
These regions encompass binding sites for TFIID,  the TATA 
sequence-binding protein (-41 to +1 relative to  the transcrip- 
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Binding of proteins to these regions i n  uiuo does not occur in 
the absence of glucocorticoid treatment  and suggests that  the 
receptor may be involved in recruitment of transcription 
factors. Thus we examined the possibility that  the effect of 
vitamin B6 concentration might be mediated at  the level of 
receptor recruitment of, or cooperation with, other  transcrip- 
tion factors. Since the  data in Fig. 1 show that  the level of 
gene expression from promoters  containing the  TFIID bind- 
ing site in combination with the GREs (pGRE2CAT and 
pGRE3CAT) was not affected by changes in vitamin B6 
concentration we next considered that the transcriptional 
modulation could be mediated through NF1. To this end, an 
oligonucleotide bearing the sequence to which NF1 binds, 
derived from the MMTV promoter (30), was inserted  into the 
simple pGREZCAT promoter between the proximal GRE and 
the TATA sequence to create pGRE2NFlCAT. The same 
oligonucleotide cloned upstream of the TATA sequence in the 
absence of the GREs, to generate pNFlCAT,  permitted analy- 
sis of vitamin effects on the transcription factor NF1 alone. 
These vectors were individually transfected  into HeLa cells, 
and  the intracellular pyridoxal phosphate  concentration was 
altered prior to treatment with dexamethasone. The  data in 
Fig. 2 show that glucocorticoid treatment  in  unaltered medium 
results in an approximate 44-fold induction in the level of 
receptor-mediated CAT gene expression derived from the 
vector containing binding sites for both the glucocorticoid 
receptor and NF1, (pGREPNF1CAT). However, this induc- 
tion was decreased to 24.7-fold, a 44% reduction, under con- 
ditions of elevated intracellular  vitamin  concentration,  and 
enhanced by 95%, to 87.2-fold, under vitamin deficiency. 
These data  are analogous to  the effects of vitamin concentra- 
tion  on gene expression induced through the complex MMTV 
promoter (Fig. 1, pGMCS), suggesting that  the transcription 
factor NF1 may  be important  in the transcriptional modula- 
tory response to vitamin Bs. Interestingly, gene expression 
mediated by the  NF1 sequence in  the absence of the GREs, 
pNFlCAT, was unaffected by modulations in intracellular 
vitamin B6 concentrations (Fig. 2, right panel). These data 
demonstrate that vitamin B6 does not mediate its  transcrip- 
tional modulatory effects through the  NF1 protein alone. 
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promoters. HeLa cells were transfected with pGMCS, pBLCAT2, pGREPCAT, or pGRE3CAT as indicated. Sixteen hours after  transfection, 
FIG. 1. Effect of vitamin Be concentration on the  level of glucocorticoid-induced gene  expression from complex and simple 
the culture media  were supplemented with either pyridoxine ( P Y R ) ,  4-deoxypyridoxine (4-DEOXY), or left unaltered (CONTROL). After 
incubation under these conditions for 48 h, cells were exposed to 100 nM dexamethasone (DEX)  or vehicle control (CON) for 8 h and  then 
harvested and assayed for CAT activity. The  data shown are from one experiment, representative of at least three independent experiments. 
TK, thymidine kinase. 
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FIG. 2. Transcription factor NF1 
is important for modulation of glu- 
cocorticoid-induced gene expres- 
sion. HeLa cells were transfected with 
(left panel) pGRE2NFlCAT or (right 
panel) pNF1CAT. Sixteen hours after 
transfection, the culture media were sup- 
plemented with either pyridoxine 
( P Y R ) ,  4-deoxypyridoxine (4-DEOXY), 
or left unaltered (CONTROL). After 48 
h  under  these conditions, cells were ex- 
posed to 100 nM dexamethasone ( D E X )  
or vehicle control (CON) for 8 h and 
then harvested and assayed for CAT ac- 
tivity. The  data shown are from one ex- 
periment, representative of at least three 
independent experiments. 
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FIG. 3. Sucrose density gradient analysis of glucocorticoid 
receptors from cells  having altered intracellular vitamin Be 
concentrations. HeLa cells were  grown in the presence or absence 
of pyridoxine and [3H]dexamethasone receptor complexes formed in 
uiuo. Heat-activated receptor complexes from the cells were incubated 
without ( -DNA)  or with specific DNA (+GRE2NF1). Following 
centrifugation the gradients were fractionated and radioactivity de- 
termined. The  data shown are  representative of two experiments. B 
refers to  the bottom of the gradient, and T refers to  the top. 
Previous studies conducted under in  vitro conditions indi- 
cated that pyridoxal phosphate could influence both glucocor- 
ticoid receptor structure  and binding to DNA (34 and refer- 
ences therein). Therefore, we examined glucocorticoid recep- 
tor activation and DNA binding under the conditions  in which 
physiological changes in vitamin B6 concentration occur 
within cells. The upper  panel in Fig. 3 shows that  in response 
to an increase in intracellular concentration of pyridoxal 
phosphate,  there  is no influence on the sedimentation profiles 
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of both activated and nonactivated glucocorticoid receptors. 
In  the upper  panel the faster-sedimenting peak (fractions 10- 
15) represents  unactivated glucocorticoid receptors, and  frac- 
tions 15-20 reflect the population of activated glucocorticoid 
receptors. These receptor preparations were incubated with a 
DNA fragment derived from pGRE2NFlCAT which encom- 
passes the GRE dimer and  NF1 binding site. The lower panel 
of Fig. 3 shows that equivalent amounts of DNA-glucocorti- 
coid receptor complexes (fractions 2-9) were formed with 
both  preparations.  These data indicate that changes in vita- 
min B6 concentration in vivo do not alter glucocorticoid 
receptor activation state or its capacity to interact with DNA. 
Since activation of the estrogen receptor is also modulated 
by changes in intracellular vitamin B6 concentration (28) we 
next  determined if the modulatory effect of the vitamin on 
these steroid-responsive promoters also exhibited a depend- 
ence on NF1. Because the estrogen receptor activates tran- 
scription through a different DNA sequence, the estrogen 
response element, we examined the effect of vitamin concen- 
tration on estrogen-induced gene expression mediated 
through an estrogen-responsive promoter either containing 
(pERENF1CAT) or lacking (pERECAT) an NF1 binding site 
in its  natural context (35). To assess estrogen inducibility, we 
transfected  these vectors into  HeLa cells which are devoid of 
estrogen receptors' but have been shown by others  and  us (24, 
31) to be capable of estrogen-induced transcriptional re- 
sponses after cotransfection with estrogen receptor expression 
vectors. After exposure of transfected cells to pyridoxine or 
4-deoxypyridoxine to  alter intracellular pyridoxal phosphate 
concentration, cells were treated with 17Sestradiol prior to 
CAT activity determination.  Interestingly, the level of estro- 
gen-induced CAT activity derived from pERECAT was not 
affected by alternations in pyridoxal phosphate concentra- 
tion,  as shown in Fig.  4, left panel. In  contrast, however, the 
level  of estrogen-induced CAT activity from the NF1-contain- 
ing  promoter,  pERENFlCAT, was significantly modulated by 
alterations in vitamin concentration. Under conditions of 
elevated vitamin  concentration, only an 8.3-fold induction in 
CAT activity was observed, which reflects a 41% reduction in 
response. Vitamin deficiency resulted in a 21.6-fold induction 
J. A. Cidlowski, unpublished data. 
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FIG. 4. Transcription factor NF1 
is important  for modulation of es- 
trogen-induced gene expression. 
HeLa cells were transfected with (left 
panel) pERECAT and pHEO or (right 
panel) pERENFlCAT and pHEO. Six- 
teen hours  after transfection, the culture 
media  were  supplemented with either 
pyridoxine ( P Y R ) ,  4-deoxypyridoxine 
(4-DEOXY), or left unaltered (CON- 
TROL). After 48 h under these condi- 
tions, cells were exposed to 5 nM 17p- 
estradiol (E2)  or vehicle control (CON) 
for  24 h and then harvested  and assayed 
for CAT activity. The data shown are 
from one experiment, representative of 
at least threq independent experiments. 













or a 54% enhancement over that observed in control medium. 
Basal CAT activity, in  the estrogen-unstimulated cells, was 
not affected by these changes in  vitamin B6 concentration. 
These observations suggest that  the requirement for NF1  in 
modulation of steroid-induced gene expression by vitamin B6 
was not restricted to glucocorticoid-inducible promoters. 
These  experiments  with pGRE2NFlCAT  and  pERENF1- 
CAT (which have different spacing between the GRE and 
NF1 binding) also suggest that  the proximity or position of 
the receptor binding sites and  the  NF1 binding site may not 
be crucial for modulation by vitamin of receptor-mediated 
gene expression. To investigate further  the role of transcrip- 
tion factor binding site orientation and spacing, we reversed 
the positions of the glucocorticoid receptor and  NF1 binding 
sites, to generate pNFlGREBCAT, and  then performed ex- 
periments to determine if the level of glucocorticoid-induced 
gene expression would  be affected by alterations  in vitamin 
Bs concentration. As shown in  the left panel of Fig. 5, when 
the  NF1 binding site was on the  5' side of the GREs,  a 56- 
fold induction  in CAT activity was observed in controls. The 
level of glucocorticoid-induced CAT gene expression was re- 
duced by 57% under  conditions of elevated vitamin  concen- 
tration, where only 23.7-fold induction was observed, and 
enhanced by 190% (164-fold induction) in vitamin deficiency. 
These results were analogous to those in which the NF1 
binding  site was located on  the 3' side of the  GREs 
(pGRESNFlCAT, right panel), where hormone-induced CAT 
activity was reduced by 53% in vitamin elevation and en- 
hanced by 130% in vitamin deficiency. We conclude from 
these observations, and those with the differently spaced 
estrogen-responsive promoters, that vitamin B6 modulation 
of hormone-induced gene expression does not depend on 
strictly conserved spacing between or orientation of the bind- 
ing sites for the receptor and NF1. It was not especially 
surprising that orientation was not crucial since other hor- 
mone-regulated promoters have transcription factor binding 
sites positioned on  both  the 5' and 3' sides of the receptor 
binding sites, and spacing between the hormone response 
elements and  the  other  transcription factor  binding  sites is 
tremendously variable (16-20,  22,  27,  35-38). 
Since several transcription factors have been implicated in 
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steroid hormone action, we wished to determine if the modu- 
latory effects of vitamin were observed under conditions 
in which the glucocorticoid receptor was allowed to  interact 
with another transcription factor. Thus we constructed a 
reporter vector whose promoter  contained binding sites for 
the glucocorticoid receptor and  the E l a  which is not endoge- 
nous to HeLa cells but can cooperate with a number of 
transcription factors (39-41). The  Ela protein  has  no DNA 
binding domain, but  it can  be converted into a DNA-binding 
protein by linking its transactivation domain to the DNA 
binding domain of a known DNA-binding protein  (25). In our 
experiments we used the well characterized chimaeric con- 
struct  in which the transcriptional  activation domain of the 
E l a  protein is fused to  the DNA binding region of the yeast 
GAL4 protein (25). This chimaeric protein, (GAL4Ela) effi- 
ciently activates transcription  in mammalian cells when 
bound to promoters  containing the GAL4 binding site (25). 
We replaced the  NF1 binding site  in pGRE2NFlCAT with 
an oligonucleotide comprising the GAL4 binding site to gen- 
erate pGRE2GAL4CAT. This plasmid, when transfected 
alone into HeLa cells, responds to glucocorticoid treatment 
with  a 25.4-fold induction  in CAT activity, as shown in Table 
I1 (CON uersus DEX, control medium). Moreover, in the 
absence of the GAL4Ela transactivator, neither basal nor 
glucocorticoid-induced CAT activity from pGRE2GAL4CAT 
was affected by alterations in intracellular  vitamin B6. Thus 
simply altering the location of the receptor binding sites 
within the promoter, by insertion of this oligonucleotide, was 
not sufficient to restore transcriptional modulation by vita- 
min. 
When  HeLa cells were cotransfected with the CAT reporter 
containing the GAL4 promoter element, PGRE~GAL~CAT, 
and the expression vector which directs expression of the 
GAL4/Ela chimaeric transactivator  protein, pGAL4Ela, we 
observed that  the level of basal (hormone-free) transcription 
was elevated in comparison with cells not transfected with 
the transactivator (Table 11). Basal CAT activity was in- 
creased from 0.41 to 5.75%. This 13-fold increase in basal 
activity is presumably derived from enhanced  transcriptional 
activity from the  Ela transactivator. This finding demon- 
strated  that  this chimaeric transactivator  protein was func- 
FIG. 5. Position-independent ef- 
fects of NF1 on modulation of glu- 
cocorticoid-induced gene expres- 
sion. HeLa cells were transfected with 
(left panel) pNFlGRE2CAT or (right 
p a n e l )  pGRE2NFlCAT. Sixteen hours 
after transfection, the cell culture media 
were supplemented with pyridoxine 
(PYR) ,  4-deoxypyridoxine (4-DEOXY), 
or left unaltered (CONTROL). After 48 
h under these conditions, cells were ex- 
posed to 100 nM dexamethasone ( D E X )  
or vehicle control (CON) for 8 h and 
then harvested and assayed for CAT ac- 
tivity. The  data shown are from one ex- 
periment, representative of at least three 
independent experiments. 
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Influence of vitamin Be on glucocorticoid-regulated gene expression 
from synthetic promoters 
The ElaGAL4 transcriptional activator cannot replace NF1 in 
restoring modulation of glucocorticoid-induced gene expression. 
HeLa cells were transfected with pGRE2GAL4CAT or pGRE2GAL4- 
CAT and pElaGAL4.  Sixteen  hours after transfection, the cell culture 
media were supplemented with pyridoxine (PYR), 4-deoxypyridoxine 
(4-DEOXY), or left unaltered (CON). After 48 hours under these 
conditions, cells were exposed to 100 nM dexamethasone (+DEX) or 
vehicle (-DEX) for 8 hours prior to CAT activity assay. The  data 
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CAT activity is expressed as percent substrate conversion. 
tional in HeLa cells. We also observed that glucocorticoid 
treatment of cells transfected with both plasmids resulted in 
5.9-fold increase in CAT activity over the level of Ela-stim- 
ulated expression, from 5.75% conversion to 33.9% conversion 
of chloramphenicol. Table I1 also shows that the level of 
glucocorticoid-induced, Ela-enhanced expression was not sig- 
nificantly altered by any  vitamin condition. Thus, despite the 
fact that another functional transcription factor interacts 
with the promoter  in the same location on the DNA  occupied 
previously by NF1, the level of glucocorticoid-induced gene 
expression was not  altered  under identical vitamin Bs concen- 
trations. Based on these  studies we conclude that  the gluco- 
corticoid receptor does not  interact or cooperate nonspecifi- 
cally with any adjacent transcription  factor,  but  interacts or 
cooperates with NF1  in  a specific manner. 
% CONVERSION 
DISCUSSION 
The level of glucocorticoid-induced gene expression through 
the complex MMTV promoter is influenced by intracellular 
pyridoxal phosphate concentration. Using reporter vectors 
whose promoters are simple, containing only glucocorticoid 
receptor binding sites and the ubiquitous TFIID binding 
sequence, we demonstrate that  the glucocorticoid receptor can 
activate  transcription efficiently in  the absence of other tran- 
scription factor binding sites. However, the level of glucocor- 
ticoid-induced gene expression derived from the simplified 
promoters was not influenced by alterations in pyridoxal 
phosphate. This was in  sharp  contrast  to  the eff cts of vitamin 
on receptor-induced gene expression through the MMTV 
promoter. Thus, binding of receptor to DNA and  transacti- 
vation account for only part of the physiological process of 
glucocorticoid hormone action,  and  other steps, which  do not 
occur at  the simplified promoters, must be involved in recep- 
tor-mediated transcription from the MMTV promoter. The 
data presented here suggest that  the effect of vitamin Bs on 
receptor-induced gene expression is mediated at these other 
steps. The importance of additional  or ancillary transcription 
factors in mediating hormone responsive gene expression has 
been clearly shown (16-20, 22, 27, 35-38). Our experiments 
demonstrated the importance of the transcription factor NF1 
in mediating the effects of vitamin B6 concentration on both 
glucocorticoid- and estrogen-induced gene expression. These 
data support the idea described above that steroid receptors 
alone may generate only part of the overall process of steroid 
hormone action. It is important to note although that our 
limited analysis shows no strict position or orientation re- 
quirements for NFl/GR cooperation, further  studies  are nec- 
essary to assess the issue of spacing. 
It will also be important to elucidate the role of other 
transcription  factors  in modulation of glucocorticoid receptor- 
induced gene expression by alterations  in  intracellular  vita- 
min & concentration.  For example, Bruggemeier et al. (37) 
suggest that  the transcription factor OTFl may be involved 
in glucocorticoid-mediated transcription  through the MMTV 
promoter. Further, Zorbas et al. (42) have reported recently 
that a  protein component of HeLa cell nuclear extracts, in 
addition to NF1, also interacts with a DNA sequence from 
20876 Vitamin Bs  and Steroid Hormone Action 
the a-globin gene promoter which is homologous in sequence 
to the oligonucleotide encompassing the NF1 binding site 
which we have used here. They have not identified this protein 
component, and  it is not known if this factor also binds to 
the MMTV promoter sequence or  interacts restrictively with 
the globin promoter. Nevertheless, these observations support 
the interesting possibility that other transcription factors, 
and  not exclusively NF1, might be  involved in modulation by 
vitamin B6 of hormone action. 
Zaret and Yamamoto (43) have suggested that glucocorti- 
coid treatment of cells induces receptor-mediated alterations 
in the structure of MMTV DNA. Subsequent work of Cordin- 
gley et al. (27) demonstrated that as a result of hormone 
treatment and glucocorticoid receptor binding, regions of 
MMTV DNA encompassing binding sites for other  transcrip- 
tion factors were protected from exonuclease digestion, indi- 
cating the receptor-induced recruitment of additional tran- 
scription factors onto  the MMTV promoter. Thus, pyridoxal 
phosphate may act to influence the ability of the receptor to 
alter  chromatin  structure  and allow access of other  transcrip- 
tion factors. Alternately, or perhaps additionally, vitamin 
may influence receptor-induced transcription factor assembly 
onto  target gene promoters. 
Another speculative mechanism through which vitamin 
may act is a direct interaction of the glucocorticoid receptor 
with the transcription factor AP1, the FOS-JUN complex, a t  
the glucocorticoid-regulated collagenase gene promoter (44- 
46). Martinez et al. (47) have shown that transcription from 
the vitellogenin gene promoter is mediated through the con- 
certed  actions of the estrogen receptor and NF1. However, 
these investigators concluded that  the estrogen receptor and 
NF1 interact, not directly with each other, but through a 
common bridging molecule. Similarly, Bastian and Nordeen 
(48) have suggested that stimulation of transcription by the 
glucocorticoid receptor and  other  transcription factors is also 
mediated through similar bridging molecules. Because we have 
shown that  the vitamin B6 concentration influences the levels 
of estrogen- and glucocorticoid-induced expression only after 
inclusion of a binding site for NF1 within the promoters, 
coactivators of this nature may be involved in vitamin B6 
modification of glucocorticoid- and estrogen-mediated gene 
expression. 
Vitamin B6 has long been recognized for its roles in normal 
growth, development, and biological function. It is  best known 
as  a cofactor in many enzymatic reactions regulating amino 
acid metabolism and nervous system function; its  importance 
in modulating lipid metabolism, gluconeogenesis, and immune 
function is also documented. The  data presented here suggest 
that this vitamin also participates in regulation of steroid 
hormone action. Intracellular pyridoxal phosphate  concentra- 
tion varies greatly in all  tissues and cell types where it has 
been measured (49-53), and  tissue-  or cell-specific concentra- 
tions of this  particular  nutrient may serve as one mechanism 
through which local response to steroid hormones may be 
regulated in a cell-specific manor. Because transcriptional 
activation of many members of the steroid hormone receptor 
superfamily is analogously affected by elevation or reduction 
in vitamin concentration, it is possible that regulation 
through  a  dietary compound may represent  a conserved mech- 
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